XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue    
Total revenue $ 2,928,654
Costs and Expenses    
Cost of product sales, excluding amortization of intangible asset 26,541
License royalty cost of sales 810,000
Amortization of intangible asset 5,387 20,594
Research and development 407,511 916,716
Selling, general and administrative expenses 5,365,647 3,474,208
Total costs and expenses 6,615,086 4,411,518
Loss before other income (expenses) (3,686,432) (4,411,518)
Other income (expenses)    
Foreign exchange (loss) gain (957) (14,629)
Interest income 470,676 12,070
Grant income 71,095 133,779
Interest expense (8,807) (8,258)
Impairment of intangible assets (39,166)
Gain (loss) on warrant liabilities 1,147,882 (619,989)
Provision for loan losses (55,000)
Total other income (expenses) 1,679,889 (591,193)
Net loss and comprehensive loss $ (2,006,543) $ (5,002,711)
Loss per share, basic (in Dollars per share) $ (0.13) $ (0.87)
Loss per share, diluted (in Dollars per share) $ (0.13) $ (0.87)
Weighted-average shares used to compute net loss per share, basic (in Shares) 16,019,787 5,744,639
Weighted-average shares used to compute net loss per share, diluted (in Shares) 16,019,787 5,744,639
Product, net    
Revenue    
Total revenue $ 346,929
Licensing    
Revenue    
Total revenue $ 2,581,725